Tetanus primary prevention: Difference between revisions

Jump to navigation Jump to search
(Created page with "{{Tetanus}} {{CMG}} {{MJM}} ==Overview== A very common primary prevention method for tetanus is vaccinating against the bacteria which causes tetanus, clostridium tetani....")
 
Line 8: Line 8:
==Vaccination==
==Vaccination==
Tetanus can be prevented by [[vaccination]].<ref name=MMWR_1991>{{cite journal | author = | title = Diphtheria, tetanus, and pertussis: recommendations for vaccine use and other preventive measures. Recommendations of the Immunization Practices Advisory committee (ACIP). | journal = MMWR Recomm Rep | volume = 40 | issue = RR-10 | pages = 1-28 | year = 1991 | id = PMID 1865873}}</ref> The [[Centers for Disease Control and Prevention|CDC]] recommends that adults receive a booster vaccine every ten years, and standard care in many places is to give the booster to any patient with a puncture wound who is uncertain of when he or she was last vaccinated, or if the patient has had fewer than 3 lifetime doses of the vaccine. The booster cannot prevent a potentially fatal case of tetanus from the current wound, as it can take up to two weeks for tetanus antibodies to form. In children under the age of seven, the tetanus vaccine is often administered as a combined vaccine, [[DPT vaccine]] or [[DTaP]], which also includes vaccines against [[diphtheria]] and [[pertussis]]. For adults and children over seven, the Td vaccine (tetanus and diphtheria) or Tdap (tetanus, diphtheria, and acellular pertussis) is commonly used.
Tetanus can be prevented by [[vaccination]].<ref name=MMWR_1991>{{cite journal | author = | title = Diphtheria, tetanus, and pertussis: recommendations for vaccine use and other preventive measures. Recommendations of the Immunization Practices Advisory committee (ACIP). | journal = MMWR Recomm Rep | volume = 40 | issue = RR-10 | pages = 1-28 | year = 1991 | id = PMID 1865873}}</ref> The [[Centers for Disease Control and Prevention|CDC]] recommends that adults receive a booster vaccine every ten years, and standard care in many places is to give the booster to any patient with a puncture wound who is uncertain of when he or she was last vaccinated, or if the patient has had fewer than 3 lifetime doses of the vaccine. The booster cannot prevent a potentially fatal case of tetanus from the current wound, as it can take up to two weeks for tetanus antibodies to form. In children under the age of seven, the tetanus vaccine is often administered as a combined vaccine, [[DPT vaccine]] or [[DTaP]], which also includes vaccines against [[diphtheria]] and [[pertussis]]. For adults and children over seven, the Td vaccine (tetanus and diphtheria) or Tdap (tetanus, diphtheria, and acellular pertussis) is commonly used.
==Tetanus toxoid==
Tetanus [[toxoid]] was first produced in 1924, and tetanus toxoid [[immunizations]] were used extensively in the armed services during World War II. Tetanus cases among this population declined from 70 in World War I (13.4/100,000 [[wounds]] and [[injuries]]) to 12 in World War II (0.44/100,000). Of the 12 case-patients, half had received no prior toxoid. Tetanus toxoid consists of a [[formaldehyde]]-treated toxin. The toxoid is standardized for potency in animal tests according to Food and Drug Administration (FDA) regulations. Occasionally, potency is mistakenly equated with Lf units, which are a measure of the quantity of toxoid, not its potency in inducing protection.
There are two types of toxoid available—[[adsorbed]] (aluminum salt precipitated) toxoid and fluid toxoid. Although the rates of seroconversion are about equal, the adsorbed toxoid is preferred because the [[antitoxin]] response reaches higher titers and is longer lasting than that following the fluid toxoid. Tetanus toxoid is available as a single-[[antigen]] preparation, combined with [[diphtheria]] toxoid as [[pediatric]] diphtheriatetanus toxoid (DT) or adult tetanus-diphtheria (Td), and with both diphtheria toxoid and acellular [[pertussis]] [[vaccine]] as DTaP or Tdap. Tetanus toxoid is also available as combined DTaP-HepB-IPV (Pediarix) and DTaP-IPV/Hib. Pediatric formulations (DT and DTaP) contain a similar amount of tetanus toxoid as adult Td, but contain 3 to 4 times as much diphtheria toxoid. Children younger than 7 years of age should receive either DTaP or pediatric DT. Persons 7 years of age or older should receive the adult formulation (adult Td), even if they have not completed a series of DTaP or pediatric DT. The use of single-antigen tetanus toxoid is not recommended. Tetanus toxoid should be given in combination with diphtheria toxoid, since periodic boosting is needed for both antigens. Two brands of Tdap are available: Boostrix (approved for persons 10 through 64 years of age) and Adacel (approved for persons 11 through 64 years of age). DTaP and Tdap vaccines do not contain thimerosal as a preservative.


==References==
==References==
{{Reflist|2}}
{{Reflist|2}}

Revision as of 15:26, 15 March 2012

Tetanus Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Tetanus from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Xray

CT scan

MRI

Ultrasound

Other Imaging Studies

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Tetanus primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Tetanus primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Tetanus primary prevention

CDC on Tetanus primary prevention

Tetanus primary prevention in the news

Blogs on Tetanus primary prevention

Directions to Hospitals Treating Tetanus

Risk calculators and risk factors for Tetanus primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Michael Maddaleni, B.S.

Overview

A very common primary prevention method for tetanus is vaccinating against the bacteria which causes tetanus, clostridium tetani.

Vaccination

Tetanus can be prevented by vaccination.[1] The CDC recommends that adults receive a booster vaccine every ten years, and standard care in many places is to give the booster to any patient with a puncture wound who is uncertain of when he or she was last vaccinated, or if the patient has had fewer than 3 lifetime doses of the vaccine. The booster cannot prevent a potentially fatal case of tetanus from the current wound, as it can take up to two weeks for tetanus antibodies to form. In children under the age of seven, the tetanus vaccine is often administered as a combined vaccine, DPT vaccine or DTaP, which also includes vaccines against diphtheria and pertussis. For adults and children over seven, the Td vaccine (tetanus and diphtheria) or Tdap (tetanus, diphtheria, and acellular pertussis) is commonly used.

Tetanus toxoid

Tetanus toxoid was first produced in 1924, and tetanus toxoid immunizations were used extensively in the armed services during World War II. Tetanus cases among this population declined from 70 in World War I (13.4/100,000 wounds and injuries) to 12 in World War II (0.44/100,000). Of the 12 case-patients, half had received no prior toxoid. Tetanus toxoid consists of a formaldehyde-treated toxin. The toxoid is standardized for potency in animal tests according to Food and Drug Administration (FDA) regulations. Occasionally, potency is mistakenly equated with Lf units, which are a measure of the quantity of toxoid, not its potency in inducing protection.

There are two types of toxoid available—adsorbed (aluminum salt precipitated) toxoid and fluid toxoid. Although the rates of seroconversion are about equal, the adsorbed toxoid is preferred because the antitoxin response reaches higher titers and is longer lasting than that following the fluid toxoid. Tetanus toxoid is available as a single-antigen preparation, combined with diphtheria toxoid as pediatric diphtheriatetanus toxoid (DT) or adult tetanus-diphtheria (Td), and with both diphtheria toxoid and acellular pertussis vaccine as DTaP or Tdap. Tetanus toxoid is also available as combined DTaP-HepB-IPV (Pediarix) and DTaP-IPV/Hib. Pediatric formulations (DT and DTaP) contain a similar amount of tetanus toxoid as adult Td, but contain 3 to 4 times as much diphtheria toxoid. Children younger than 7 years of age should receive either DTaP or pediatric DT. Persons 7 years of age or older should receive the adult formulation (adult Td), even if they have not completed a series of DTaP or pediatric DT. The use of single-antigen tetanus toxoid is not recommended. Tetanus toxoid should be given in combination with diphtheria toxoid, since periodic boosting is needed for both antigens. Two brands of Tdap are available: Boostrix (approved for persons 10 through 64 years of age) and Adacel (approved for persons 11 through 64 years of age). DTaP and Tdap vaccines do not contain thimerosal as a preservative.

References

  1. "Diphtheria, tetanus, and pertussis: recommendations for vaccine use and other preventive measures. Recommendations of the Immunization Practices Advisory committee (ACIP)". MMWR Recomm Rep. 40 (RR-10): 1–28. 1991. PMID 1865873.